search
Back to results

TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock (TRANSPORT)

Primary Purpose

Septic Shock, Anemia, Cancer

Status
Unknown status
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
Liberal Red blood cell transfusion
Restrictive Red blood cell transfusion
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock focused on measuring Septic Shock, Anemia, cancer, erythrocyte transfusion

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > 18 years
  • Evolutive (complete remission < 2 years) malignant solid tumor or chronic or acute hematological malignancy
  • Septic shock defined as:
  • Presumed or documented infection
  • Acute circulatory failure defined as hypotension requirement of vasoactive drugs for more than one hour (norepinephrine or epinephrine ≥ 0.1 µg/kg/min)
  • Tissue hypoxia defined by arterial lactate level > 2 mmol/L within 12 hours prior to inclusion
  • Hemoglobin level < 9 g/dL
  • Informed consent from patients or surrogates

Exclusion Criteria:

  • Acute life-threatening bleeding
  • Ongoing acute coronary syndrome or any other acute ischemic condition
  • End-of-life decisions at the time of ICU admission
  • Refusal of transfusions for personal beliefs
  • Lack of social security coverage
  • Pregnancy or breastfeeding

Sites / Locations

  • hopital CochinRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Liberal strategy

Restrictive strategy

Arm Description

Maintain a hemoglobin level > 9 g/dL during the first 48 hours of resuscitation of septic shock

Maintain a hemoglobin level > 7 g/dL during the resuscitation of septic shock

Outcomes

Primary Outcome Measures

Tissue oxygenation
Percentage of patients with normal arterial lactate level at 12 hours (<=2 mmol/L) or a relative decrease (or clearance) of arterial lactate level above 30% according to the formula (lactateH0 - lactateH12)/lactate H0*100. lactateH0 : arterial lactate level at inclusion lactateH12 : arterial lactate level at 12h

Secondary Outcome Measures

Tissue oxygenation 6
Percentage of patients with normal arterial lactate level at 6 hours (<=2 mmol/L) or a relative decrease (or clearance) of arterial lactate level above 30% according to the formula (lactateH0 - lactateH6)/lactate H0*100. lactateH0 : arterial lactate level at inclusion lactateH6 : arterial lactate level at 6h
Tissue oxygenation 24
Percentage of patients with normal arterial lactate level at 24 hours (<=2 mmol/L) or a relative decrease (or clearance) of arterial lactate level above 30% according to the formula (lactateH0 - lactateH24)/lactate H0*100. lactateH0 : arterial lactate level at inclusion lactateH24 : arterial lactate level at 24h
Tissue oxygenation 48
Percentage of patients with normal arterial lactate level at 48 hours (<=2 mmol/L) or a relative decrease (or clearance) of arterial lactate level above 30% according to the formula (lactateH0 - lactateH48)/lactate H0*100. lactateH0 : arterial lactate level at inclusion lactateH48 : arterial lactate level at 48h
Mortality 7
Percentage of Death at 7 days
Mortality 28
Percentage of Death at 28 days
ICU mortality
Percentage of Death in ICU at 28 days
Hospital mortality
Percentage of Death in Hospital at 28 days
Change in SOFA 24
Differences between SOFA score at inclusion (SOFA0) and SOFA score at 24 hours. The sequential organ failure assessment score (SOFA score) ranges from 0 (normal patient) to 24 (most severe patient). Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-800.
Change in SOFA 48
Differences between SOFA score at inclusion (SOFA0) and SOFA score at 48 hours. The sequential organ failure assessment score (SOFA score) ranges from 0 (normal patient) to 24 (most severe patient). Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-800.
Change in SOFA 72
Differences between SOFA score at inclusion (SOFA0) and SOFA score at 72 hours. The sequential organ failure assessment score (SOFA score) ranges from 0 (normal patient) to 24 (most severe patient). Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-800.
Change in SOFA 7d
Differences between SOFA score at inclusion (SOFA0) and SOFA score at day 7. The sequential organ failure assessment score (SOFA score) ranges from 0 (normal patient) to 24 (most severe patient). Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-800.
ventilator free days
ventilator free days (VFDs) are defined as follows: VFDs=0: If the patient dies before 28 days. VFDs=(28-x): If the patient is success-fully weaned from mechanical ventilation within 28 days, where x is the number of days spent receiving mechanical ventilation. VFDs=0: If the patient requires mechanical ventilation for 28 days or more.
vasopressor free days
vasopressor free days (VaFDs) are defined as follows: VaFDs=0: If the patient dies before 28 days. VaFDs=(28-x): If the patient is successfully weaned from vasopressor within 28 days, where x is the number of days spent with vasopressor. VaFDs=0: If the patient requires vasopressor for 28 days or more.
renal replacement therapy free days
renal replacement therapy free days (RRFDs) are defined as follows: RRFDs=0: If the patient dies before 28 days. RRFDs=(28-x): If the patient is successfully weaned from renal replacement therapy within 28 days, where x is the number of days spent with vasopressor. RRFDs=0: If the patient requires renal replacement therapy for 28 days or more.
ICU length of stay
time spent in ICU from inclusion censored at 28 days
Ischemic
Incidence of ischemic event during the first 28 days (stroke, myocardial infarction, mesenteric infarction)
thrombosis
Incidence of deep venous thrombosis or pulmonary embolism during the first 28 days
TRIALI
Incidence of transfusion-related acute lung injury during the first 28 days
Transfusion reaction
Incidence of side effects of transfusions during the first 28 days (fever, chills, hemolysis)

Full Information

First Posted
February 8, 2019
Last Updated
March 27, 2019
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT03837171
Brief Title
TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock
Acronym
TRANSPORT
Official Title
Stratégie Transfusionnelle érythrocytaire Dans la réanimation du Choc Septique du Patient d'Onco-hématologie : Essai randomisé Multicentrique TRANSPORT [TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock]
Study Type
Interventional

2. Study Status

Record Verification Date
February 2019
Overall Recruitment Status
Unknown status
Study Start Date
March 24, 2019 (Actual)
Primary Completion Date
February 20, 2021 (Anticipated)
Study Completion Date
February 20, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Septic shock is a frequent complication associated with high mortality in patients with malignancies. The best transfusion strategy (restrictive or liberal) for the resuscitation of septic shock remains a controversial issue, in relation with potentially discrepant goals of tissue oxygenation and transfusion sparing. In this study, the investigators propose to address the efficacy of two RBC transfusion strategies (liberal or restrictive) in restoring appropriate tissue oxygenation as well as their tolerance. The investigators designed a prospective randomized multicenter trial aimed at comparing liberal and restrictive RBC transfusion strategies applied during the first 48 hours of resuscitation in cancer patients with septic shock and anemia.
Detailed Description
Septic shock is a frequent complication in patients with malignancies and remains affected with a mortality rate higher than 50%. Red blood cell (RBC) transfusion remains a major issue for critically ill cancer patients who frequently display anemia as a result of malignant bone marrow involvement or imposed by cytotoxic treatments. However, our current practice of RBC transfusion in the intensive care unit (ICU) is drawn from general populations. Several case-control studies suggested that RBC transfusion was associated with higher mortality and increased incidence of ICU-acquired complications in critically ill patients. In 1999, a restrictive strategy of non-leucodepleted RBC transfusion to maintain hemoglobin above 7 g/dL was shown to be as effective as a liberal transfusion strategy aimed to maintain haemoglobin > 10 g/dL in critically ill patients. As of today, the current recommendations for RBC transfusion remain largely based on this study which excluded patients with a history of anemia. Leucodepletion that is now routinely implemented in France might be associated with fewer transfusion-related events. Indeed, some recent studies challenged the restrictive strategy and suggested that a higher transfusion threshold might be beneficial in septic patients for whom oxygen delivery is of paramount importance. Most importantly, a hemodynamic support algorithm for severe sepsis also known as early goal-directed therapy (EGDT) included a hematocrit target of 30%. The majority of EGDT-treated patients received RBC transfusion within the early 72 hours of resuscitation, thereby representing a major difference compared to standard treatment, but the prognostic value of RBC transfusion was not specifically assessed. A recent case-control study also suggested that RBC transfusion was an independent predictor of survival in patients with septic shock. Cancer patients with septic shock and hemoglobin level < 9 g/dL initiation will be randomized to the interventional arm (liberal transfusion strategy to maintain hemoglobin > 9 g/dL) or to the control arm (restrictive transfusion strategy to maintain hemoglobin > 7 g/dL) in a 1:1 ratio. Patients from the intervention arm will have their hemoglobin level maintained above 9 g/dL for the whole time under vasopressors, for a maximum of 28 days. After weaning from vasopressor, the transfusion threshold will be lowered to 7 g/dL as recommended by the SSC guidelines. In case of shock relapse requiring reintroduction of vasopressors, the transfusion threshold will be upgraded back to 9 g/dL until next catecholamine weaning. In the control arm, the transfusion threshold will be 7 g/dL until ICU discharge regardless of catecholamine administration. The primary objective of the study will be the restoration of tissue oxygenation as assessed by lactate clearance at 12 hours following randomization. The secondary endpoints will be related to restoration of tissue oxygenation at alternative time points (6h, 24h, 36h, 48h) as assessed as above, the 7-day, 28-day, in-ICU and in-hospital mortality rate, changes in organ failures over the first 48 hours and 7 days, duration for organ failure supports, the development of acute ischemic and thrombotic events (myocardial infarction, mesenteric ischemia, ischemic stroke, limb ischemia, deep venous thrombosis) over the first 7 days. An interim analysis on the primary endpoint has been pre-planned at the end of the follow up of half of patients included.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock, Anemia, Cancer
Keywords
Septic Shock, Anemia, cancer, erythrocyte transfusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
260 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Liberal strategy
Arm Type
Active Comparator
Arm Description
Maintain a hemoglobin level > 9 g/dL during the first 48 hours of resuscitation of septic shock
Arm Title
Restrictive strategy
Arm Type
Experimental
Arm Description
Maintain a hemoglobin level > 7 g/dL during the resuscitation of septic shock
Intervention Type
Biological
Intervention Name(s)
Liberal Red blood cell transfusion
Intervention Description
Hemoglobin level will be maintained above 9 g/dL (liberal strategy) for the first 48 hours following randomization. After 48 hours, indications of RBC transfusions will be at the discretion of attending physicians in patients with persistent circulatory failure. After resolution of acute circulatory failure, a 7 g/dL transfusion threshold will be recommended regardless of the allocation arm. In case of subsequent episodes of septic shock, the transfusion strategy will be at the discretion of attending physicians
Intervention Type
Biological
Intervention Name(s)
Restrictive Red blood cell transfusion
Intervention Description
Hemoglobin level will be maintained above 7 g/dL (restrictive strategy) during all the stay in ICU
Primary Outcome Measure Information:
Title
Tissue oxygenation
Description
Percentage of patients with normal arterial lactate level at 12 hours (<=2 mmol/L) or a relative decrease (or clearance) of arterial lactate level above 30% according to the formula (lactateH0 - lactateH12)/lactate H0*100. lactateH0 : arterial lactate level at inclusion lactateH12 : arterial lactate level at 12h
Time Frame
12 hours
Secondary Outcome Measure Information:
Title
Tissue oxygenation 6
Description
Percentage of patients with normal arterial lactate level at 6 hours (<=2 mmol/L) or a relative decrease (or clearance) of arterial lactate level above 30% according to the formula (lactateH0 - lactateH6)/lactate H0*100. lactateH0 : arterial lactate level at inclusion lactateH6 : arterial lactate level at 6h
Time Frame
6 hours
Title
Tissue oxygenation 24
Description
Percentage of patients with normal arterial lactate level at 24 hours (<=2 mmol/L) or a relative decrease (or clearance) of arterial lactate level above 30% according to the formula (lactateH0 - lactateH24)/lactate H0*100. lactateH0 : arterial lactate level at inclusion lactateH24 : arterial lactate level at 24h
Time Frame
24 hours
Title
Tissue oxygenation 48
Description
Percentage of patients with normal arterial lactate level at 48 hours (<=2 mmol/L) or a relative decrease (or clearance) of arterial lactate level above 30% according to the formula (lactateH0 - lactateH48)/lactate H0*100. lactateH0 : arterial lactate level at inclusion lactateH48 : arterial lactate level at 48h
Time Frame
48 hours
Title
Mortality 7
Description
Percentage of Death at 7 days
Time Frame
7 days
Title
Mortality 28
Description
Percentage of Death at 28 days
Time Frame
28 days
Title
ICU mortality
Description
Percentage of Death in ICU at 28 days
Time Frame
28 days
Title
Hospital mortality
Description
Percentage of Death in Hospital at 28 days
Time Frame
28 days
Title
Change in SOFA 24
Description
Differences between SOFA score at inclusion (SOFA0) and SOFA score at 24 hours. The sequential organ failure assessment score (SOFA score) ranges from 0 (normal patient) to 24 (most severe patient). Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-800.
Time Frame
24 hours
Title
Change in SOFA 48
Description
Differences between SOFA score at inclusion (SOFA0) and SOFA score at 48 hours. The sequential organ failure assessment score (SOFA score) ranges from 0 (normal patient) to 24 (most severe patient). Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-800.
Time Frame
48 hours
Title
Change in SOFA 72
Description
Differences between SOFA score at inclusion (SOFA0) and SOFA score at 72 hours. The sequential organ failure assessment score (SOFA score) ranges from 0 (normal patient) to 24 (most severe patient). Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-800.
Time Frame
72 hours
Title
Change in SOFA 7d
Description
Differences between SOFA score at inclusion (SOFA0) and SOFA score at day 7. The sequential organ failure assessment score (SOFA score) ranges from 0 (normal patient) to 24 (most severe patient). Vincent JL, de Mendonça A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793-800.
Time Frame
7 days
Title
ventilator free days
Description
ventilator free days (VFDs) are defined as follows: VFDs=0: If the patient dies before 28 days. VFDs=(28-x): If the patient is success-fully weaned from mechanical ventilation within 28 days, where x is the number of days spent receiving mechanical ventilation. VFDs=0: If the patient requires mechanical ventilation for 28 days or more.
Time Frame
28 days
Title
vasopressor free days
Description
vasopressor free days (VaFDs) are defined as follows: VaFDs=0: If the patient dies before 28 days. VaFDs=(28-x): If the patient is successfully weaned from vasopressor within 28 days, where x is the number of days spent with vasopressor. VaFDs=0: If the patient requires vasopressor for 28 days or more.
Time Frame
28 days
Title
renal replacement therapy free days
Description
renal replacement therapy free days (RRFDs) are defined as follows: RRFDs=0: If the patient dies before 28 days. RRFDs=(28-x): If the patient is successfully weaned from renal replacement therapy within 28 days, where x is the number of days spent with vasopressor. RRFDs=0: If the patient requires renal replacement therapy for 28 days or more.
Time Frame
28 days
Title
ICU length of stay
Description
time spent in ICU from inclusion censored at 28 days
Time Frame
28 days
Title
Ischemic
Description
Incidence of ischemic event during the first 28 days (stroke, myocardial infarction, mesenteric infarction)
Time Frame
28 days
Title
thrombosis
Description
Incidence of deep venous thrombosis or pulmonary embolism during the first 28 days
Time Frame
28 days
Title
TRIALI
Description
Incidence of transfusion-related acute lung injury during the first 28 days
Time Frame
28 days
Title
Transfusion reaction
Description
Incidence of side effects of transfusions during the first 28 days (fever, chills, hemolysis)
Time Frame
28 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 18 years Evolutive (complete remission < 2 years) malignant solid tumor or chronic or acute hematological malignancy Septic shock defined as: Presumed or documented infection Acute circulatory failure defined as hypotension requirement of vasoactive drugs for more than one hour (norepinephrine or epinephrine ≥ 0.1 µg/kg/min) Tissue hypoxia defined by arterial lactate level > 2 mmol/L within 12 hours prior to inclusion Hemoglobin level < 9 g/dL Informed consent from patients or surrogates Exclusion Criteria: Acute life-threatening bleeding Ongoing acute coronary syndrome or any other acute ischemic condition End-of-life decisions at the time of ICU admission Refusal of transfusions for personal beliefs Lack of social security coverage Pregnancy or breastfeeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Frederic PENE, MD, PhD
Phone
158414677
Ext
+33
Email
frederic.pene@cch.aphp.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Matthieu RESCHE-RIGON, MD PhD
Phone
142499742
Ext
+33
Email
matthieu.resche-rigon@univ-paris-diderot.fr
Facility Information:
Facility Name
hopital Cochin
City
Paris
ZIP/Postal Code
75005
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
frederic PENE, MD

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock

We'll reach out to this number within 24 hrs